Roche's Perjeta wins priority review for earlier use; FDA rebuffs new Xarelto use in stent patients;

 @FiercePharma: Will the new weight loss drugs ever prosper? The NYT ticks off the odds stacked against them: Article | Follow @FiercePharma

> Roche's ($RHHBY) breast-cancer treatment Perjeta stepped on the FDA's priority-review track for a new use in patients who haven't yet had surgery. Release

> The FDA pulled back from approving a new use for Johnson & Johnson ($JNJ) and Bayer's clot-fighter Xarelto, to reduce the rate of stent thrombosis in patients with acute coronary syndrome. Report

> The private equity firm Blackstone Group aims to cash in on India's Emcure Pharma, which has filed for a potentially $120 million initial public offering; the firm has a significant minority stake. Report

> Abbott Laboratories ($ABT) is among the baby formula makers under investigation in China for potential violations of anti-monopoly laws. Report

> The effects of new-generation anticoagulant Xarelto can be partially reversed by prothrombin complex concentrates in the event of severe bleeding, a new study found. Release

> Several Indian drugmakers won FDA approval to sell their versions of Merck & Co.'s ($MRK) migraine drug Maxalt-MLT, including Aurobindo Pharma and Glenmark. Report

Medical Device News

 @FierceMedDev: Zoll grabs Minnesota startup with FDA challenges. News | Follow @FierceMedDev

 @MarkHFierce: Today's Dx Extra: a look at a colon cancer test that could detect tumor cells before they take root. DxExtra | Follow @MarkHFierce

 @DamianFierce: Our latest industry voices piece: A Dx insider weighs in on the implications of SCOTUS' MYGN ruling. More | Follow @DamianFierce

 @MichaelGFierce: 'Bioadhesive' coating helps oral drugs deliver payload. Item | Follow @MichaelGFierce

> Roche buys blood diagnostics outfit for $220M. Story

> Sequenta raises $20M for cancer diagnostics. Report

> ArthroCare forks over $45M for sinus surgical tool company. News

Biotech News

 @FierceBiotech: UPDATED: A long lineup of potential buyers crowds Onyx picture. Article | Follow @FierceBiotech

 @JohnCFierce: MannKind shoulders $160M in debt for PhIII inhaled-insulin gamble. Story | Follow @JohnCFierce

 @RyanMFierce: Celgene, others regenerate biotech Tengion's finances with $33.6M. Report | Follow @RyanMFierce

> Achillion shares skid lower after FDA puts a hold on hep C drug. More

> What's the most valuable drug in the global pipeline? Report

Pharma Manufacturing News

 @CarlyHFierce: 160 of India's manufacturing facilities prepared for new EU regulations going into effect today. Item | Follow @CarlyHFierce

>  With Aspen deal, Merck finally able to shrink legacy Organon sites. Story

> Med Prep slapped with consent decree as FDA eyes compounders. More

> Glass particles once again trigger Fresenius Kabi recall. Article

> King Pharma settles for $2.2M after violating pharma emissions standards. Story

Biotech Research News

 @EmilyMFierce: Mouse models predict chemo treatment response in humans. Report | Follow @EmilyMFierce

> Texas A&M launches multimillion-dollar genomics research project. More

> Report: U.K. health body stifling stem cell research. News

> Nonprofit licenses MS mouse model to Biogen Idec to develop new therapies. Story

And Finally... Lottery tickets as rewards for staying HIV-free cut infections by 25% in an African study. Report

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.